A meta-analysis reported inferior efficacy of PD-1/PD-L1 inhibitors in EGFR-mutant NSCLC compared with EGFR-wildtype disease [5], consistent with our findings (Figure 3); similarly, reduced ICI responsiveness has been reported in tumors with EGFR mutations or ALK rearrangements [13]. Here, EGFR is linked to non-small cell lung carcinoma.